Biomedical Engineering Reference
In-Depth Information
2. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ,
Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamox-
ifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin
Oncol 23:9312-9318
3. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynods C,
Couch FJ, Lingle WL, Weinshilboum RM, Barr Fritcher EG, Barr Fritcher AM, Desta Z,
Nguyen A, Flockhart DA, Perez EA, Ingle JN (2006) The impact of cytochrome P450 2D6
metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121
4. Lim HS, Lee HJ, Lee KS, Lee ES, Jang IJ, Ro J (2007) Clinical implications of CYP2D6 geno-
types predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol
25:3837-3845
5. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Parker BA, Wu AHB, Pierce
JP (2010) Tamoxifen metabolite concentrations, CYP2D6 genotype and breast cancer out-
comes. J Clin Oncol 89(5):718-725
6. Sterns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z,
Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministra-
tion of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst
95:1758-1764
7. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM,
Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6
genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast can-
cer treatment. Clin Pharmacol Ther 80:61-74
8. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Faszat LF (2010)
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamox-
ifen: a population based cohort study. BMJ 340:c693
9. Wu AH, Pike MC, Williams LD, Spicer D, Tseng CC, Churchwell MI, Doerge DR (2007)
Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J Clin
Oncol 25:3024-3030
10. Lee KH, Ward BA, Desta Z, Flockhart DA (2003) Jones DR (2003) Quantification of tamox-
ifen and three metaoblites in plasma by high-performance liquid chromatography with
fluorescence detection: application to a clinical trial. J Chromatogr B 791:245-253
11. Furlanut M, Franceschi L, Pasqual E, Bacchetti S, Poz D, Giorda G, Cagol PP (2007) Tamoxifen
and its main metabolites serum and tissue concentration in breast cancer women. Ther Drug
Monit 29:349-352
12. Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA (2005) Identification and
quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem
mass spectrometry. J Chromatogr A 1082:6-14
13. National Cancer Institute. Studying blood samples from women with breast cancer or ductal
carcinoma in situ who are receiving tamoxifen. NCT00764322.
http://www.clinicaltrials.gov/
14. ACC/AHA/SCAI 2005 (2006) Guideline Update for Percutaneous Coronary Intervention—
Summary Article. A Report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001
Guidelines for Percutaneous Coronary Intervention). Circulation 113:156-175
15. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, Lachno DR, Salazar D,
Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharma-
cokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost
5:2429-2436
16. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM,
Macias W, Braunwald E, Sabatine MS (2009) Cytochrome P-450 polymorphisms and response
to clopidogrel. N Engl J Med 360:354-362
17. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G,
Beygui F, Bensimon G, Funck-Bretano C, Montalescot G (2009) Cytochrome P450 2C19
